Author: Relmada Therapeutics

Posted Date:

May 7, 2026

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

Relmada Therapeutics

May 7, 2026
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

Relmada Therapeutics

May 5, 2026
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Relmada Therapeutics

March 19, 2026
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

Relmada Therapeutics

March 12, 2026
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Relmada Therapeutics

March 9, 2026
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

Relmada Therapeutics

March 9, 2026
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Relmada Therapeutics

March 9, 2026